CN1343727A - Polymannuronic acid sulfate - Google Patents
Polymannuronic acid sulfate Download PDFInfo
- Publication number
- CN1343727A CN1343727A CN 00111372 CN00111372A CN1343727A CN 1343727 A CN1343727 A CN 1343727A CN 00111372 CN00111372 CN 00111372 CN 00111372 A CN00111372 A CN 00111372A CN 1343727 A CN1343727 A CN 1343727A
- Authority
- CN
- China
- Prior art keywords
- acid
- alcohol
- polymannuronic
- aids
- vitriol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A polymannuronic acid sulfate with anti-AIDS activity contains the primary molecular skeletons: the mannuronic acid linked with beta-D (1-4) and the guluronic acid linked with beta-L (1-4). The SO3Na is introduced to the hydroxy position on C2 and C3 of carbon ring. Its preparing process includes dewatering sodium alginate, dissolving, centrifugal separation, classifying with alcohol, dissolving the classified and degradated alginic acid, neutralizing with alkali, separating out solid, dewatering with alcohol, sulforating with chlorosulfonic acid, neutralizing with alkali, dewatering with alcohol and drying. It can be used to prepare anti-AIDS medicines.
Description
The present invention relates to a kind of new macromolecular compound, particularly relate to a kind of medicinal polymannuronic acid vitriol.
Acquired immune deficiency syndrome (AIDS) (AIDs) is one of the most dangerous transmissible disease in the whole world, finds the first patient so far from 1981, and global the infected is near 4,000 ten thousand, and every day is still with 1.6 ten thousand new the infecteds' speed increase.At present, the anti-AIDs medicine of FDA approval listing only has tens, and the general action link is single, be prone to resistance, toxic side effect is big, costs an arm and a leg, can not control the rapid spread of AIDs effectively, the anti-AIDs medicine of therefore developing high-efficiency low-toxicity is a very urgent task.
The purpose of this invention is to provide a kind of polymannuronic acid vitriol, it is a kind of new compound, can treat the multiple disease that comprises acquired immune deficiency syndrome (AIDS).
A kind of polymannuronic acid vitriol, the main molecules skeleton that it is characterized in that it are the guluronic acid that the mannuronic acid of β-D-(1 → 4) connection is connected with β-L (1 → 4), and wherein the golonic acid fragment accounts for 10-30%, at isocyclic C
2And C
3On hydroxy position introduce a SO
3Na.
A kind of method for preparing polymannuronic acid vitriol, it is characterized in that making sodium alginate dehydration back dissolving, centrifugation is also used alcohol grading, the alginic acid of having degraded the dissolving that classification is obtained with the alkali neutralization, is used dehydration of alcohol after isolating solid, use the chlorsulfonic acid sulfonation again, with the alkali neutralization, use dehydration of alcohol, drying then.
A kind of polymannuronic acid vitriol is characterized in that having the activity of anti-AIDS, is used to prepare the medicine of anti AIDS virus.
A kind of polymannuronic acid vitriol is characterized in that having the activity of preventing and treating type hepatitis disease, is used to prepare the medicine of preventing and treating hepatitis B.
The present invention is a kind of new macromolecular compound, and it can be as the new drug of anti-AIDS and control hepatitis B, not only low price, and high-efficiency low-toxicity.
Below by embodiment the present invention is described.
Get sea-tangle, be soaked in water, to remove impurity and to make it softening, liquefaction is convenient in stripping and slicing, uses Na again after washing
2CO
3Liquefaction, proportion carries out coarse filtration near 1 impurity is floating to the upper strata, with the smart filter of 300～500 purpose filtering nets, filters residue again.Condense with calcification (or acidization), to make the alignic moisture content of generation be 60-65% (by weight) to press dewatering again.In the alcohol medium,, leach the solid sodium alginate then with the alkali neutralization.With 95% alcohol washing sodium alginate, dehydration makes its moisture controlled about 20% again, with the dissolving of this sodium alginate, make its aqueous solution that becomes 1% (by weight), added the algin enzyme and be under 7 and 35 ℃ the condition reaction 5 hours at PH, heating makes enzyme deactivation then, cooling, centrifugal, use alcohol grading, the sodium alginate of the degraded that classification is obtained dissolving again, make it become 2% the aqueous solution, regulate PH to 2.85, isolate polymannuronic acid with NaOH.With this polymannuronic acid dehydration of alcohol, dry, its moisture content is controlled at about 12%, make its sulfonation with chlorsulfonic acid, generate Sulfated polymannuronic acid, with among the NaOH and after be converted to the polymannuronic acid sodium sulfate salt, use dehydration of alcohol, drying is polymannuronic acid vitriol of the present invention, contains the fragment of the guluronic acid vitriol about 20% in its main molecules skeleton.
Macromolecular compound of the present invention, its organic sulfur content is 7-12% (by weight), and white is extremely faint yellow, amorphous powder, odorless, it is little salty to distinguish the flavor of, have draw moist, limiting viscosity η=7.0-10.0, soluble in water, insoluble in acetone, chloroform and ether, the ratio MW/Mn of weight-average molecular weight and number-average molecular weight is less than 1.8, PH=6.0-7.5.
Make anti-AIDS (AIDs) experiment in vitro with compound polymannuronic acid vitriol of the present invention and show, this compound can suppress human AIDS poison (HIV-1) significantly to a kind of T lymphocyte subculture in vitro separately strain (MT
4) acute infection of cell and the chronic infection of another kind of T lymphocyte subculture in vitro separately strain H9 cell, the propagation of acquired immune deficiency syndrome (AIDS) clinical separation strain in human peripheral blood lymphocytes also there is obvious restraining effect, do in the body experiment with compound of the present invention and can make that virus titer and viral messenger RNA(mRNA) (mRNA) copy number obviously reduce in simian acquired immunodeficiency syndrome poison (SIV) the infected monkey blood plasma, anti-body contg in the obvious rising monkey blood plasma, and to blood CD
4Positive cell has the certain protection effect, and can obviously reduce murine leukemia virus (LP-BM
5) strain infecting mouse spleen virus antigen positive cell number, reduce the model mouse spleen index, improve white corpuscle, red corpuscle and the hemoglobin level of model mouse; Further experiment shows that the mechanism of action of this compound is relevant with the enhance immunity function with the absorption that suppresses viral reverse transcriptase activity, viral interference and cell.
Also done the experiment of hepatitis virus resisting with compound of the present invention.Wherein experiment in vitro shows, this compound can obviously reduce people's liver cancer 2215 cell (HepG of hepatitis B virus (HBV) transfection
22215) antigen amount can suppress the HBV-DNA polymerase activity, and experiment in vitro shows that also this compound has obvious restraining effect to duplicating of hepatitis B virus; Experiment shows that this compound can obviously reduce duck hepatitis B virus (DHBV) infected duck serum DHBsAg and DHBV-DNA level in the body, and experiment in vivo and vitro shows that all this compound all has remarkable restraining effect to hepatitis B virus duplication.Show also that with experiment this compound can obviously reduce D-galactosamine and CCl
4Due to acute liver damage mice serum glutamic-oxal(o)acetic transaminase (ALT), gpt (AST) activity; the pathology that can significantly alleviate liver changes; obviously reduce hydroxyproline content in chronic hepatic injury rat blood serum ALT and AST activity and the liver organization; significantly reduce serum globulin content; improve the albumins/globulins ratio; alleviate chronic hepatic injury rat liver fibrosis degree, to the obvious provide protection of having of experimental liver injury.
Claims (4)
1, a kind of polymannuronic acid vitriol, the main molecules skeleton that it is characterized in that it are the guluronic acid that the mannuronic acid of β-D-(1 → 4) connection is connected with β-L (1 → 4), and wherein the golonic acid fragment accounts for 10-30%, at isocyclic C
2And C
3On hydroxy position introduce a SO
3Na.
2, a kind of method for preparing polymannuronic acid vitriol, it is characterized in that making sodium alginate dehydration back dissolving, centrifugation is also used alcohol grading, the alginic acid of having degraded the dissolving that classification is obtained with the alkali neutralization, is used dehydration of alcohol after isolating solid, use the chlorsulfonic acid sulfonation again, with the alkali neutralization, use dehydration of alcohol, drying then.
3, a kind of polymannuronic acid vitriol is characterized in that having the activity of anti-AIDS, is used to prepare the medicine of anti AIDS virus.
4, a kind of polymannuronic acid vitriol is characterized in that having the activity of preventing and treating type hepatitis disease, is used to prepare the medicine of preventing and treating hepatitis B.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00111372 CN1111541C (en) | 2000-09-15 | 2000-09-15 | Polymannuronic acid sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00111372 CN1111541C (en) | 2000-09-15 | 2000-09-15 | Polymannuronic acid sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1343727A true CN1343727A (en) | 2002-04-10 |
| CN1111541C CN1111541C (en) | 2003-06-18 |
Family
ID=4581290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00111372 Expired - Lifetime CN1111541C (en) | 2000-09-15 | 2000-09-15 | Polymannuronic acid sulfate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111541C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721611A1 (en) * | 2005-04-21 | 2006-11-15 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| EP1721612A3 (en) * | 2003-10-24 | 2007-05-09 | N.V. Nutricia | Immunemodulating oligosaccharides |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| US8277836B2 (en) | 1998-08-11 | 2012-10-02 | N.V. Nutricia | Carbohydrates mixture |
| CN105343121A (en) * | 2015-09-28 | 2016-02-24 | 青岛海洋生物医药研究院股份有限公司 | Application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation |
| CN105748506A (en) * | 2016-03-03 | 2016-07-13 | 青岛海洋生物医药研究院股份有限公司 | Application of alginate sulfate in preparation of medicines and health products used for preventing and treating diseases caused by human papilloma virus |
-
2000
- 2000-09-15 CN CN 00111372 patent/CN1111541C/en not_active Expired - Lifetime
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8277836B2 (en) | 1998-08-11 | 2012-10-02 | N.V. Nutricia | Carbohydrates mixture |
| US8580295B2 (en) | 1998-08-11 | 2013-11-12 | N.V. Nutricia | Carbohydrates mixture |
| EP1911453A3 (en) * | 2003-10-24 | 2008-09-03 | N.V. Nutricia | Immunemodulating oligosaccharides |
| EP2123282A3 (en) * | 2003-10-24 | 2010-01-20 | N.V. Nutricia | Immunemodulating oligosaccharides |
| EP1721612A3 (en) * | 2003-10-24 | 2007-05-09 | N.V. Nutricia | Immunemodulating oligosaccharides |
| US9084433B2 (en) | 2004-06-06 | 2015-07-21 | N. V. Nutricia | Intestinal barrier integrity |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| EP1721611A1 (en) * | 2005-04-21 | 2006-11-15 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| CN105343121A (en) * | 2015-09-28 | 2016-02-24 | 青岛海洋生物医药研究院股份有限公司 | Application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation |
| CN105343121B (en) * | 2015-09-28 | 2018-07-06 | 青岛海洋生物医药研究院股份有限公司 | Application of the guluronic acid sulfuric ester in the drug for preparing anti-hepatitis B virus |
| CN105748506A (en) * | 2016-03-03 | 2016-07-13 | 青岛海洋生物医药研究院股份有限公司 | Application of alginate sulfate in preparation of medicines and health products used for preventing and treating diseases caused by human papilloma virus |
| CN105748506B (en) * | 2016-03-03 | 2018-08-17 | 青岛海洋生物医药研究院股份有限公司 | Application of the alginic acid sulfuric ester in the drug and health products for preparing prevention and treatment disease caused by Subclinical papillomavirus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1111541C (en) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Astic et al. | The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice | |
| CN1111541C (en) | Polymannuronic acid sulfate | |
| CA2006119C (en) | Anti-aids viral agents and anticancer action | |
| Michel et al. | Nephropathy associated with infection by human immunodeficiency virus: a report on 11 cases including 6 treated with zidovudine | |
| CN107118303A (en) | A kind of preparation and application of modified wheat stalk cellulose | |
| CN106306731A (en) | Sulfur-free synthetic processing wet method of konjac refined powder | |
| CN102558379A (en) | Method for extraction and deproteinization of hop polysaccharide | |
| CN105418410A (en) | Emodin derivatives and application thereof in preparation of anti-HIV-1 medicines | |
| Ismail et al. | Antioxidant and antiviral activity of sulfated polysaccharides derived from two Sargassum species of Red Sea Egypt | |
| EP0395757B1 (en) | Process for extracting physiologically active substance from pine seed shells and antiinfectant prepared mainly from the extract | |
| CN105560352B (en) | A kind of anti-duck virus hepatitis astragalus polyose phosphorylated molecules modification method | |
| CN101011412A (en) | Usage of low-molecular-weight algal polysaccharide sulfate in preparation of medicament for treating hepatic disease | |
| CN100562526C (en) | Oligomeric glucose sulfuric ester and preparation method thereof | |
| CN110734505A (en) | Preparation method of carboxymethyl chitin | |
| JP2005510490A (en) | Anti-HSV drugs for blocking HSV-1 and HSV-2 replication and methods for producing substances having anti-HSV activity | |
| CA1106282A (en) | Arterial polysaccharide complex, process for its preparation and its use in human therapy | |
| KR20220041945A (en) | Spent turmeric - methods and compositions thereof | |
| CN101011411A (en) | Usage of algal polysaccharide sulfate in preparation of medicament for treating hepatic disease | |
| CN1256349C (en) | Prepn and use of curcuma oligosaccharide sulfate derivative | |
| JP4540133B2 (en) | Novel phosphorylated β-glucan having anti-AIDS virus activity and drug for treating retrovirus infection containing the same | |
| WO2019000335A1 (en) | Standard library of low-molecular-weight heparin, dalteparin sodium, and preparation method thereof | |
| JP2004244367A (en) | Mammal cytoprotective agent containing lignophenol derivative | |
| CN114671960B (en) | Preparation method of corn stigma polysaccharide and application of corn stigma polysaccharide in blood sugar reducing product | |
| US2727889A (en) | Fractionation of alginic acid sulfate | |
| US5241091A (en) | Method of extracting a physiological active substance from the husks of pine nuts and anti-contagion medicine made of said extract as principal raw material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20030618 |